News • 03/13/2023 | Finance

DBV Technologies Update

News • 03/07/2023

DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old

News • 03/02/2023 | Finance

DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document

News • 03/02/2023 | Finance

DBV Technologies Reports Full Year 2022 Financial Results and Business Update

News • 02/27/2023

DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023

News • 02/21/2023 | Conferences | Science

DBV Technologies to Participate in Upcoming AAAAI 2023 Congress

News • 02/10/2023 | Conferences | Finance

DBV Technologies to Participate in Upcoming Investor Conference

News • 01/23/2023 | Finance

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

News • 01/04/2023

Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2022

News • 12/23/2022

DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial

News • 12/08/2022

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2022

News • 11/22/2022 | Conferences

DBV Technologies to Participate in Upcoming Investor Conference

News • 11/14/2022 | Science

EPITOPE Study Results: Phase 3, Randomized, Double-blind, Placebo-controlled Study of Epicutaneous Immunotherapy in Peanut-allergic Toddlers

News • 11/14/2022 | Science

REDUCTION IN REACTION SEVERITY FOLLOWING 12 MONTHS OF EPICUTANEOUS IMMUNOTHERAPY WITH PEANUT PATCH IN TODDLERS

News • 11/09/2022 | Medical Congresses

DBV Technologies to Highlight New Clinical Data at ACAAI 2022

News • 11/03/2022 | Finance

DBV Technologies Reports Third Quarter Financial Results and Business Update

News • 10/31/2022 | Finance

DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update

News • 10/20/2022

Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2022

News • 10/03/2022

DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors

News • 09/21/2022

DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial

News • 09/07/2022

DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut-Allergic Children Ages 4 to 7 Years

News • 09/02/2022 | Conferences

DBV Technologies to Present at Upcoming Investor Conferences

News • 08/01/2022 | Finance

DBV Technologies Reports Second Quarter 2022 Financial Results

News • 07/27/2022 | Finance

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

News • 07/20/2022

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2022

News • 06/29/2022 | Conferences

DBV Technologies to Participate in Upcoming EAACI 2022 Congress

News • 06/16/2022 | Conferences

DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York

News • 06/09/2022 | Corporate | Finance

DBV Technologies Announces Private Placement Financing of $194 Million

News • 06/07/2022 | Science

DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut- Allergic Toddlers

News • 05/17/2022 | Corporate

Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2022

News • 05/12/2022 | General Meeting

DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting

News • 05/05/2022

DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM)

News • 05/02/2022

DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq

News • 05/02/2022

DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results

News • 04/25/2022

DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments

News • 04/21/2022

Ordinary and Extraordinary General Meeting of May 12, 2022

News • 04/14/2022 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2022

News • 03/21/2022 | Science

Effect of Allergy Specialty Care of Healthcare Utilization Among Children with Peanut Allergy in the United States

News • 03/21/2022 | Science

Pooled Safety Data from Phase 3 Studies of Epicutaneous Immunotherapy for Peanut Allergy in Children Aged 4-11 Years

News • 03/14/2022 | Conferences

DBV Technologies to Present at the Oppenheimer’s 32nd Annual Healthcare Conference

News • 03/11/2022 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 28, 2022

News • 03/09/2022 | Finance

DBV Technologies Announces Filing of 2021 Annual Report on Form 10-K and 2021 Universal Registration Document

News • 03/03/2022 | Finance

DBV Technologies Reports Full Year 2021 Financial Results and Recent Business Updates

News • 02/24/2022 | Finance

DBV Technologies to Report Full Year 2021 Financial Results and Business Updates on March 3, 2022

News • 02/22/2022 | Conferences

DBV Technologies to Participate in Upcoming AAAAI 2022 Congress

News • 02/14/2022 | Conferences

DBV Technologies to Present at the 11th Annual SVB Leerink Global Healthcare Conference

News • 02/09/2022 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2022

News • 01/21/2022 | Finance

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

News • 01/12/2022

Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2021

News • 01/07/2022 | Conferences

DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference

News • 12/20/2021 | Science

DBV Technologies Provides Update on Investigational Viaskin™ Peanut

News • 12/10/2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2021

News • 11/24/2021 | Conferences

DBV Technologies to Participate in an Upcoming Investor Conference

News • 11/04/2021 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2021

News • 11/01/2021

DBV Technologies to Highlight New Long-term Data from REALISE Trial at ACAAI 2021

News • 10/26/2021 | Finance

DBV Technologies Reports Third Quarter 2021 Financial Results and Recent Regulatory Developments

News • 09/08/2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of August 31, 2021

News • 08/31/2021 | Conferences

DBV Technologies to Participate at Upcoming Investor Conferences

News • 08/09/2021 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2021

News • 08/06/2021

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

News • 08/02/2021

DBV Technologies Reports Second Quarter 2021 Financial Results and Recent Business Developments

News • 07/26/2021

DBV Technologies to Report First Half 2021 Financial Results and Business Updates on August 2, 2021

News • 07/07/2021 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2021

News • 06/15/2021 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2021

News • 06/02/2021 | Conferences

DBV Technologies to Present at Upcoming Investor Conferences

News • 05/19/2021 | General Meeting

DBV Technologies Announces Results of its 2021 Ordinary and Extraordinary General Meeting and the Appointment of Dr. Adora Ndu, Pharm.D., J.D., and Dr. Ravi Madduri Rao, M.D., Ph.D., as Members of its Board of Directors

News • 05/17/2021 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2021

News • 05/05/2021

DBV Technologies Announces Filing of its First Form 10-Q for the First Quarter of 2021

News • 05/03/2021

DBV Technologies Reports Q1 2021 Financial Results

News • 04/29/2021 | Conferences

DBV Technologies to Participate in Upcoming Investor Conferences

News • 04/28/2021 | General Meeting

AGM 2021 – Total Number of Voting Rights and Existing Number of Shares

News • 04/28/2021

Ordinary and Extraordinary General Meeting of May 19, 2021 to be Held in Closed Virtual Session Due to COVID-19 Pandemic

News • 04/02/2021

DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors

News • 04/02/2021 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2021

News • 03/26/2021

DBV Technologies Announces a New Chair of its Audit Committee and Date of its Annual General Meeting

News • 03/17/2021 | Finance

DBV Technologies Announces Filing of 2020 Annual Report on Form 10-K and 2020 Universal Registration Document

News • 03/12/2021 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 28, 2021

News • 03/11/2021 | Finance

DBV Technologies Reports Full-Year 2020 Financial Results and Recent Business Developments

News • 03/05/2021 | Conferences

DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference

News • 03/04/2021 | Finance

DBV Technologies Announces Date Change for Reporting Full Year 2020 Financial Results

News • 03/01/2021 | Finance

DBV Technologies to Report Full Year 2020 Financial Results on March 4, 2021

News • 02/24/2021 | Conferences

DBV Technologies to Participate in Upcoming AAAAI 2021 Congress

News • 02/22/2021 | Corporate

DBV Technologies Announces Appointment of Michele F. Robertson as Chief Legal Officer

News • 02/19/2021 | Conferences

DBV Technologies to Participate in SVB Leerink Global Partners Healthcare Conference

News • 02/11/2021 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2021

News • 01/29/2021 | Finance

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

News • 01/14/2021 | Science

DBV Technologies Provides Update on Investigational Viaskin™ Peanut for Children Ages 4-11 Years

News • 01/07/2021 | Corporate

DBV Technologies Announces Change in U.S. Reporting Status and Final Approval of Global Restructuring Process

News • 01/05/2021 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2020

News • 12/15/2020 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2020

News • 11/24/2020 | Corporate

DBV Technologies Announces Leadership Changes

News • 11/11/2020 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2020

News • 11/10/2020 | Science

DBV Technologies to Highlight Data on Viaskin™ Peanut Treatment Delivery and Patient Experience at ACAAI 2020

News • 11/09/2020 | Conferences

DBV Technologies to Participate in Upcoming Investor Conferences

News • 11/02/2020

DBV Technologies Announces Filing and Validation of Marketing Authorization Application for Viaskin™ Peanut by European Medicines Agency

News • 10/30/2020

DBV Technologies Reports September 30, 2020 Cash Position

News • 10/08/2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2020

News • 09/15/2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of August 31, 2020

News • 09/09/2020 | Corporate

DBV Technologies Announces Leadership Changes

News • 09/02/2020 | Conferences

DBV Technologies to Participate in Multiple September Investor Conferences

News • 08/12/2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2020

News • 08/04/2020

DBV Technologies Receives Complete Response Letter from FDA for Viaskin Peanut BLA in Children Ages 4-11 Years

News • 07/31/2020 | Finance

DBV Technologies Reports First Half 2020 Financial Results

News • 07/20/2020 | Finance

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

News • 07/15/2020 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2020

News • 07/10/2020

DBV Technologies Announces Publication of PEOPLE Phase III Open-Label Extension Study Evaluating Viaskin Peanut in The Journal of Allergy and Clinical Immunology

News • 06/26/2020

DBV Technologies Provides Operational and Business Update

News • 06/11/2020 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2020

News • 06/04/2020 | Conferences

DBV Technologies to Present Data on Epicutaneous Immunotherapy and Food Allergy Quality of Life at EAACI Digital Congress 2020

News • 06/02/2020 | Conferences

DBV Technologies To Present at the Goldman Sachs 41st Annual Global Healthcare Conference

News • 05/12/2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2020

News • 04/30/2020

DBV Technologies Reports March 31, 2020 Cash Position

News • 04/20/2020 | General Meeting

DBV Technologies Announces Results of its 2020 Ordinary and Extraordinary General Meeting

News • 04/15/2020 | General Meeting

Ordinary and Extraordinary General Meeting of April 20, 2020

News • 04/15/2020 | Corporate

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 04/10/2020 | General Meeting

Ordinary and Extraordinary General Meeting of April 20, 2020 to be Held in Closed Virtual Session Due to COVID-19 Pandemic

News • 04/06/2020 | General Meeting

AGM 2020 – Notice of Meeting

News • 03/30/2020 | General Meeting

Ordinary and Extraordinary General Meeting of April 20, 2020

News • 03/20/2020 | Finance

DBV Technologies Announces Filing of 2019 Universal Registration Document and 2019 Annual Report on Form 20-F

News • 03/17/2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 29, 2020 and March 4, 2020

News • 03/16/2020 | Science

DBV Technologies Provides Update on Viaskin Peanut BLA for Children Ages 4-11 Years

News • 03/16/2020 | General Meeting

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 03/04/2020 | Finance

DBV Technologies Reports Full-Year 2019 Financial Results and Provides Business Update

News • 03/04/2020 | Finance

DBV Technologies Announces Closing of Underwriters’ Option to Purchase Additional Ordinary Shares in the Form of American Depositary Shares in Connection With its Global Offering

News • 03/02/2020 | Finance

DBV Technologies Announces Partial Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs)

News • 02/24/2020 | Science

DBV Technologies to Present Detailed Safety and Efficacy Data of Viaskin Peanut at AAAAI 2020

News • 02/21/2020

DBV Technologies Announces FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment of Peanut Allergy in Children

News • 02/10/2020 | Conferences

DBV Technologies to Present at the SVB Leerink 9th Annual Global Healthcare Conference

News • 02/07/2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2020 and February 4, 2020

News • 02/06/2020 | Corporate

DBV Technologies Announces Appointment of Pascal Wotling as Chief Technical Operations Officer

News • 02/04/2020

DBV Technologies Announces Closing of Global Offering

News • 01/30/2020

DBV Technologies Announces Pricing of $153.7 million (€139.8 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares

News • 01/29/2020

DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports December 31, 2019 Cash Position

News • 01/15/2020 | Finance

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

News • 01/14/2020

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 01/08/2020 | Science

DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut Allergy

News • 01/02/2020 | Corporate

DBV Technologies Announces Appointment of Ramzi Benamar as Chief Financial Officer

News • 12/10/2019

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 11/19/2019

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 11/05/2019 | Conferences

DBV Technologies to Present at the Stifel 2019 Healthcare Conference

News • 10/24/2019 | Conferences | Medical Congresses

DBV Technologies to Highlight the Burden of Peanut Allergy and Patient Experiences with Viaskin Peanut at ACAAI 2019

News • 10/16/2019 | Corporate | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 10/15/2019 | Finance

DBV Technologies Announces Closing of Global Offering

News • 10/10/2019 | Finance

DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs)

News • 10/09/2019 | Finance

DBV Technologies Announces Pricing of $125 million (€114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares

News • 10/08/2019 | Finance

DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash Position

News • 10/04/2019

DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy

News • 10/02/2019

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 09/19/2019

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 08/07/2019

DBV Technologies Submits Biologics License Application to U.S. Food and Drug Administration for Viaskin Peanut for the Treatment of Peanut Allergy

News • 08/01/2019 | Finance

DBV Technologies Reports First Half 2019 Financial Results

News • 07/18/2019

Amendment to the DBV Technologies Liquidity Contract with NATIXIS ODDO BHF and Half-Year Report

News • 07/12/2019

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 06/26/2019 | Corporate

DBV Technologies Announces Appointment of Pharis Mohideen, M.D., as Chief Medical Officer

News • 06/11/2019 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 06/03/2019 | Corporate

DBV Technologies to Attend Upcoming Investor Conferences

News • 06/01/2019 | Conferences | Medical Congresses

DBV Technologies to Present Data from Epicutaneous Immunotherapy at EAACI 2019

News • 05/24/2019 | General Meeting

DBV Technologies Announces Results of its 2019 Ordinary and Extraordinary General Meeting and the Appointment of Viviane Monges to the Board of Directors

News • 05/14/2019 | Corporate

DBV Technologies Announces Departure of Deputy CEO David Schilansky

News • 05/03/2019 | General Meeting

Ordinary and Extraordinary General Meeting of May 24, 2019 Procedures for Obtaining Preparatory Documents for the General Meeting

News • 05/02/2019 | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

News • 04/30/2019 | Finance

DBV Technologies Reports March 31, 2019 Cash Position

News • 04/10/2019 | Finance

Information regarding the total number of voting rights and total number of shares of the Company

News • 04/08/2019 | Finance

DBV Technologies Announces Closing of Global Offering

News • 04/08/2019 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 04/05/2019 | Finance

DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares (ADS)

News • 04/04/2019 | Finance

DBV Technologies Announces Pricing of $70.4 million (€62.7 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares

News • 04/03/2019 | Finance

DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares

News • 04/01/2019 | Finance

DBV Technologies Announces Filing of 2018 “Document de Référence” and 2018 Annual Report on Form 20-F

News • 03/06/2019 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 03/05/2019 | Finance

DBV Technologies Reports Full Year 2018 Financial Results and Provides Operational Update

News • 03/05/2019 | Corporate

DBV Technologies Announces Appointment of Michel de Rosen as Non-Executive Chairman of the Board of Directors

News • 03/01/2019

DBV Technologies to Attend Upcoming Investor Conferences

News • 02/22/2019 | Science

DBV Technologies Announces Publication of Detailed Phase III Trial Results Evaluating Viaskin Peanut as a Novel Treatment for Peanut Allergy in The Journal of the American Medical Association

News • 02/13/2019

DBV Technologies Provides Update on Regulatory Status of Viaskin Peanut for the Treatment of Peanut-Allergic Children 4 to 11 Years of Age

News • 02/08/2019

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 02/04/2019

DBV Technologies to Present Data on Epicutaneous Immunotherapy at AAAAI 2019

News • 02/01/2019 | Conferences

DBV Technologies to Present at the 8th Annual Leerink Partners Global Healthcare Conference

News • 01/17/2019

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

News • 01/11/2019

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 01/03/2019

DBV Technologies Expands and Strengthens Leadership Team

News • 12/19/2018

DBV Technologies Provides Update on Viaskin Peanut for Children Four to 11 Years of Age

News • 12/12/2018

DBV Technologies Highlights Data Supporting Induction of Immunotolerance Through the Skin at Inflammatory Skin Disease Summit 2018

News • 12/06/2018 | Corporate | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 11/20/2018

DBV Technologies Presents Data at ACAAI 2018 on Investigational Viaskin Peanut for the Treatment of Peanut-Allergic Children

News • 11/16/2018

DBV Technologies Appoints Daniel Tassé as Chief Executive Officer

News • 11/09/2018

DBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the 2018 ACAAI Meeting

News • 11/07/2018 | Corporate | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 10/30/2018 | Finance

DBV Technologies Reports September 30, 2018 Cash Position

News • 10/26/2018 | Clinical

DBV Technologies Announces Initiation of Part B of Phase III Study in Peanut-Allergic Toddlers

News • 10/22/2018 | Corporate

DBV Technologies Announces Submission of Biologics License Application for Viaskin Peanut to the U.S. Food and Drug Administration

News • 10/09/2018 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 09/25/2018

DBV Technologies to Present at the Cantor Global Healthcare Conference

News • 09/12/2018

DBV Technologies Announces Positive DSMB Review of Part A of Phase III Study in Peanut-Allergic Toddlers

News • 09/07/2018 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 09/07/2018 | Finance

DBV Technologies Reports First Half 2018 Financial Results

News • 09/05/2018 | Science

DBV Technologies, Geneva University Hospitals and BioNet-Asia Presented Additional Phase I Data on the Use of an Investigational Epicutaneous Patch in Boosting Pertussis Vaccination at the European Congress of Immunology

News • 08/31/2018

DBV Technologies to Attend Upcoming Investor Conferences

News • 07/27/2018 | Finance

DBV Technologies Reports June 30, 2018 Cash Position

News • 07/26/2018

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

News • 07/19/2018

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 07/13/2018

Half-Year Report on the DBV Technologies Liquidity Contract and Transfer to Oddo BHF

News • 06/26/2018 | Corporate

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 06/22/2018

DBV Technologies Announces Results of its 2018 Ordinary and Extraordinary General Meeting and the Appointment of Joan Schmidt as Executive Vice President, General Counsel

News • 06/11/2018 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 06/05/2018 | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

News • 06/01/2018 | General Meeting

Annual General Meeting, June 22, 2018

Procedures for Obtaining Preparatory Documents for the General Meeting
Download PDF

News • 05/29/2018 | General Meeting

Annual General Meeting, June 22, 2018

Information regarding the total number of voting rights and total number of shares of the Company on May 18th, 2018

Download PDF

News • 05/29/2018 | Medical Congresses

DBV Technologies Shows Commitment to the Development of Treatments for Food Allergies at EAACI 2018

News • 05/16/2018 | Corporate

DBV Technologies Announces Appointment of Michel de Rosen to its Board of Directors

News • 05/14/2018

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 05/14/2018 | Corporate

DBV Technologies Partners with FARE to Help Raise Awareness of Food Allergies in Support of the 21st Anniversary of Food Allergy Awareness Week

News • 05/08/2018 | Medical Congresses

DBV Technologies to Present New Clinical Data from Viaskin Platform at the 2018 EAACI Meeting

News • 05/01/2018 | Corporate

DBV Technologies to Attend Upcoming Investor Conferences

News • 04/27/2018 | Finance

DBV Technologies Reports March 31, 2018 Cash Position

News • 04/05/2018

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 04/03/2018 | Conferences

DBV Technologies to Attend the 11th Kempen Life Sciences Conference

News • 03/26/2018 | Finance

DBV Technologies Announces Closing of Underwriters’ Option to Purchase Additional Shares in Global Offering

News • 03/23/2018 | Finance

DBV Technologies Announces Closing of Global Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

News • 03/21/2018 | Finance

DBV Technologies Announces Pricing of $150.0 million (€122.5 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares

News • 03/20/2018 | Finance

DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares

News • 03/16/2018 | Corporate | Finance

DBV Technologies Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F

News • 03/14/2018 | Finance

DBV Technologies Reports Full Year 2017 Financial Results

News • 03/07/2018 | Conferences

DBV Technologies to Present at the Barclays Global Healthcare Conference

News • 02/28/2018 | Corporate

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 02/26/2018 | Clinical

DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients

News • 02/20/2018 | Finance

DBV Technologies Reports December 31, 2017 Cash Position

News • 02/14/2018 | Clinical

DBV Technologies Provides Update on Regulatory Progress for Viaskin Peanut

News • 02/13/2018 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 02/12/2018 | Science

DBV Technologies to Highlight Viaskin Technology Platform at the 2018 AAAAI/WAO Joint Congress

News • 02/01/2018 | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

News • 01/16/2018 | Finance

Half-Year Report on the DBV Technologies Liquidity Contract with Natixis

News • 01/12/2018 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 01/03/2018 | Conferences

DBV Technologies to Present at the 36th Annual J.P. Morgan Healthcare Conference

News • 12/22/2017

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 11/19/2017

DBV Technologies Announces Positive Topline Safety Results from REALISE Phase III Trial of Viaskin Peanut for the Treatment of Peanut-Allergic Patients

News • 10/20/2017

DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut- Allergic Patients Four to 11 Years of Age

News • 10/12/2017

DBV Technologies Announces Completion of Blinded Period in REALISE Study of Viaskin Peanut

News • 10/03/2017 | Corporate | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 09/05/2017

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 09/01/2017 | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

News • 08/29/2017 | Clinical

DBV Technologies Announces Completion of Enrollment in Phase III Extension Study of Viaskin Peanut

News • 08/02/2017 | Clinical

DBV Technologies Initiates Phase III Study of Viaskin Peanut in Peanut-Allergic Patients One to Three Years of Age

News • 07/28/2017 | Finance

DBV Technologies Reports First Half 2017 Financial Results

News • 07/07/2017 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 07/05/2017 | Finance

Half-Year Report on the DBV Technologies Liquidity Contract with Natixis

News • 06/17/2017 | Science

DBV Technologies Highlights Poster Presentations on EPIT® at the 2017 EAACI Congress

News • 06/15/2017 | General Meeting

DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General Meeting

News • 06/12/2017

DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General Meeting

News • 06/01/2017 | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

News • 05/12/2017 | Corporate | Finance

Ordinary and Extraordinary General Meeting of June 15, 2017 Procedures for Obtaining Preparatory Documents for the General Meeting

News • 05/08/2017 | Science

DBV Technologies Highlights Research Presentation of EPIT® for the Treatment of Crohn’s Disease at Digestive Disease Week 2017

News • 05/02/2017 | Conferences | Finance

DBV Technologies to Attend Upcoming Investor Conferences

News • 04/28/2017 | Finance

DBV Technologies Reports March 31, 2017 Cash Position

News • 04/05/2017 | Conferences

DBV Technologies to Attend the 10th Kempen Life Sciences Conference

News • 04/05/2017 | Conferences

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 03/30/2017 | Clinical | Corporate

DBV Technologies, BioNet-Asia and Geneva University Hospitals Announce Phase I Trial Results of Viaskin rPT in Pertussis Booster Vaccination

News • 03/22/2017 | Corporate | Finance

DBV Technologies Announces Filing of its 2016 “Document de Référence” and Annual Report on Form 20-F

News • 03/15/2017 | Finance

DBV Technologies Reports Full Year 2016 Financial Results

News • 03/10/2017 | Clinical | Product Candidates

DBV Technologies Announces Completion of Enrollment of the REALISE Study in Peanut Allergic Children

News • 03/07/2017 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 03/05/2017 | Clinical | Conferences

Data at AAAAI 2017 Show Lasting Response and Favorable Safety Profile of Investigational Agent, Viaskin Peanut, Throughout Three Years of Treatment of Peanut Allergic Children

News • 03/01/2017 | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

News • 02/20/2017 | Finance

DBV Technologies Reports December 31, 2016 Cash Position

News • 02/10/2017 | Conferences | Corporate | Science

DBV to Present Data at the 2017 AAAAI Meeting Highlighting the Therapeutic Potential of EPIT®

News • 02/05/2017 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 02/03/2017 | Clinical | Product Candidates

DBV Technologies Announces Completion of Enrollment of Phase IIA Study of Viaskin Milk for the Treatment of Pediatric Eosinophilic Esophagitis

News • 01/26/2017 | Conferences

DBV Technologies to Present at the LEERINK Partners 6th Annual Global Healthcare Conference

News • 01/09/2017 | Corporate | Finance

DBV Technologies Announces Financial Calendar 2017

News • 01/04/2017 | Finance

DBV Technologies Presents its Half-year Statement of the Liquidity Contract

News • 01/04/2017 | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 12/07/2016 | Corporate | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 11/17/2016 | Clinical | Product Candidates

DBV Technologies, BioNet-Asia and Geneva University Hospitals Complete Dosing in First Cohort of Phase I Study of Viaskin rPT for Booster Vaccination Against Pertussis

News • 11/16/2016 | Corporate | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 11/12/2016 | Science

DBV Technologies Announces Poster Presentations at the 2016 American College of Allergy, Asthma, and Immunology Meeting

News • 11/10/2016 | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

News • 11/08/2016 | Clinical | Product Candidates

DBV Technologies Completes Enrollment of Phase II Study of Viaskin Milk for the Treatment of Milk Allergic Patients

News • 11/03/2016 | Finance

DBV Technologies Reports September 30, 2016 Cash Position

News • 10/26/2016 | Clinical | Product Candidates

DBV Technologies Announces Publication of Positive Viaskin Peanut Data From NIAID-Sponsored Phase II Academic Study in the Journal of Allergy and Clinical Immunology

News • 10/24/2016 | Clinical | Product Candidates

Topline Results from Two-Year Follow-Up Study of Viaskin Peanut Show Long-Lasting and High Levels of Desensitization to Peanut

News • 10/17/2016 | Corporate | Finance

Monthly information regarding the total number of voting rights and total number of shares of the Company

News • 09/21/2016 | Product Candidates

DBV Technologies Receives FDA Fast Track Designation for Viaskin Milk for the Treatment of Cow’s Milk Protein Allergy

News • 09/06/2016 | Clinical | Partnership

DBV Technologies, BioNet-Asia and the Geneva University Hospitals Initiate Phase I Study of Viaskin rPT for Pertussis Booster Vaccination

News • 09/01/2016 | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

News • 08/01/2016 | Clinical

DBV Technologies Announces Expansion of Clinical Program of Viaskin Peanut for the Treatment of Peanut Allergy

News • 07/28/2016 | Finance

DBV Technologies Reports Interim Financial Results for the First Half of 2016

News • 07/11/2016 | Finance

Half year update on the DBV Technologies liquidity agreement

News • 07/05/2016 | Corporate

DBV Technologies Proudly Welcomes Dr. Lucia Septién as Chief Medical Officer

News • 06/27/2016 | Clinical

DBV Technologies Announces Completion of Recruitment in Global Phase III Study of Viaskin Peanut for the Treatment of Peanut Allergic Children

News • 06/21/2016 | General Meeting

DBV Announced Results of its 2016 Annual Meeting of Shareholders

News • 06/21/2016 | General Meeting

DBV Technologies Expands its Board of Directors with the Appointments of Claire Giraut and Maïlys Ferrere

News • 06/16/2016 | Conferences

DBV Technologies to Present at the JMP Securities Life Sciences Conference

News • 06/15/2016 | Product Candidates | Science

Late-Breaking Presentation at EAACI Highlights Viaskin® Peanut Data Providing Biomarker Insights for Monitoring Treatment Progression

News • 06/13/2016 | Science

DBV Technologies Announces Publication of Preclinical Data in JACI Suggesting EPIT® Provides Sustained Protection Against Anaphylaxis

News • 06/07/2016 | Corporate

DBV Technologies Announces Appointment of Leading Japanese Allergist, Dr. Motohiro Ebisawa, to its Scientific Advisory Board

News • 06/01/2016 | Conferences | Science

DBV Technologies Data at EAACI 2016 Highlight Its Expansive Product Development in Food Allergies

News • 05/31/2016 | Partnership

DBV Technologies and Nestlé Health Science Form Collaboration to Develop and Commercialize a Novel Diagnostic Test for Pediatric Milk Allergy

News • 05/30/2016 | General Meeting

Mixed General Assembly of June 21, 2016 Procedures for obtaining preparatory documents for the Assembly

News • 05/20/2016 | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

News • 04/29/2016 | Finance

DBV Technologies Reports March 31, 2016 Cash Position

News • 04/28/2016 | Corporate

DBV Technologies Announces Filing of 2015 “Document de Référence” and 2015 Annual Report on Form 20-F

News • 04/27/2016 | Conferences

DBV Technologies to Attend Upcoming Investor Conferences

News • 04/11/2016 | Science

DBV Technologies Announces Publication of Experimental Data on Targeted Regulatory T Cell Induction during Epicutaneous Immunotherapy

News • 04/07/2016 | Finance

DBV Technologies Reports Full Year 2015 Financial Results

News • 03/06/2016 | Product Candidates

Additional Phase IIb Trial Results with Viaskin Peanut Presented at the 2016 AAAAI Meeting Continue to Support Treatment Safety, Efficacy and Compliance

News • 03/04/2016 | Product Candidates

DBV Technologies Announces Presentation from NIAID-sponsored CoFAR6 Phase II Trial Reaffirming Viaskin® Peanut Safety and Efficacy

News • 03/01/2016 | Conferences

DBV Technologies to Attend Upcoming Investor Conferences and Events

News • 02/25/2016 | Product Candidates

DBV Technologies Announces Publication of Phase Ib Trial Results in the Journal of Allergy and Clinical Immunology (JACI) Supporting Safety and Tolerability of Viaskin® Peanut

News • 02/15/2016 | Finance

DBV Technologies Reports December 31, 2015, Cash Position

News • 02/10/2016 | Conferences | Finance

DBV Technologies to Present New Data at the 2016 AAAAI Annual Meeting

News • 02/08/2016 | Conferences

DBV Technologies to Present at the LEERINK Partners 5th Annual Global Healthcare Conference

News • 01/26/2016 | Corporate

DBV Technologies Proudly Welcomes Edward Jordan as Senior Vice President Commercial Operations North America

News • 01/08/2016

DBV Technologies Presents its Half-year Statement of the Liquidity Contract

News • 01/08/2016 | Finance

DBV Technologies Announces 2016 Financial Calendar

News • 01/07/2016 | Finance

DBV Technologies Presents its Half-year Statement of the Liquidity Contract

News • 12/10/2015 | Science

First Experimental Results for the Treatment of Colitis with Viaskin® will be presented at the Crohn’s & Colitis Foundation of America’s 2015 Advances in IBD Conference (AIBD)

News • 12/07/2015 | Clinical | Product Candidates

DBV Technologies Announces Initiation of Phase III Study of Viaskin® Peanut for the Treatment of Peanut Allergic Children

News • 11/18/2015 | Clinical | Science

DBV Technologies to Present Preclinical Data on its Viaskin® Technology for RSV Vaccination at the 2015 RSV Vaccines for the World Meeting

News • 11/12/2015 | Clinical

DBV Technologies Announces Enrollment of First Patient in Phase IIA Study in Pediatric Eosinophilic Esophagitis

News • 11/03/2015 | Corporate | Finance

DBV Technologies Reports Interim Financial Results for the third quarter of 2015

News • 10/22/2015 | Corporate

DBV Technologies Announces the Appointment of Michael J. Goller to its Board of Directors

News • 10/14/2015 | Clinical | Product Candidates

DBV Technologies Announces First Patient Enrolled in Phase II Study of Viaskin Milk

News • 10/05/2015 | Clinical | Product Candidates

Follow-Up Study of Viaskin® Peanut Shows Significant Increase in Peanut Consumption and Treatment Benefit in Peanut Allergic Children

News • 09/11/2015 | Corporate | Finance

DBV Technologies To Enter SBF 120 Index

News • 09/08/2015 | Conferences

DBV Technologies Invited to Present at the Royal Society of Medicine 11th Medical Innovations Summit

News • 09/03/2015 | Conferences | Corporate

DBV Technologies to Attend Upcoming Investor Conferences and Events

News • 08/31/2015 | General Meeting

DBV Technologies’ Extraordinary General Assembly on September 21, 2015

News • 08/26/2015 | Conferences | Finance

DBV Technologies to Attend the Goldman Sachs European Biotech Symposium

News • 07/28/2015 | Corporate | Finance

DBV Technologies Reports Financial Results   for the First Six Months of 2014  

News • 07/27/2015 | Corporate | Finance

DBV Technologies Reports Interim Financial Results for the First Half of 2015

News • 07/20/2015 | Finance

DBV Technologies Announces Closing of $281.5 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

News • 07/17/2015 | Clinical | Product Candidates

DBV Technologies Completes last “food challenge” visit of last PeanutAllergic patient in VIPES Phase IIb Clinical Study

News • 07/15/2015 | Corporate | Finance

DBV Technologies Announces Pricing of Underwritten Public Offering of Ordinary Shares

News • 07/14/2015 | Corporate | Finance

DBV Technologies Announces Launch of Proposed Underwritten Public Offering of Ordinary Shares

News • 07/08/2015 | Science

IND Acceptance from FDA for a proof-ofconcept trial using Viaskin® Milk in MilkInduced Eosinophilic Esophagitis in Children

News • 07/02/2015 | Corporate | Finance

DBV Technologies announces the filing of a registration statement on Form F-1 in view of an offering of new shares in the form of American Depositary Shares, as well as the filing of its Reference Document

News • 07/02/2015 | Corporate | Finance

Half year update on the DBV Technologies liquidity agreement

News • 06/30/2015 | Corporate

DBV Technologies Announces Completion of Part A of the MILES Study Evaluating the Safety of Viaskin® Milk in Pediatric Cow’s Milk Allergy

News • 06/26/2015 | Corporate

DBV Technologies Proudly Welcomes Dr. Hugh Sampson as Chief Scientific Officer

News • 06/23/2015 | Corporate

DBV Technologies’ June 23, 2015 Combined Shareholders’ Meeting

News • 06/23/2015 | Corporate

DBV Technologies Confirms Planned Initiation of Viaskin® Peanut Global Phase III Clinical Trial in Children Following Endof-Phase II Meeting with FDA and PIP approval by EMA

News • 06/10/2015 | Science

Key Scientific Data Demonstrating that Epicutaneous Administration May Reactivate Protective Immunity against Pertussis in an experimental model published in Vaccine

News • 06/08/2015 | Conferences | Science

DBV Technologies Presents Clinical and Scientific Data at the EAACI Congress

News • 06/04/2015 | Corporate | Science

DBV Technologies Announces EMA Paediatric Committee (PDCO) positive opinion on the Paediatric Investigation Plan for Viaskin® Peanut for the Treatment of Peanut Allergic Children

News • 06/02/2015 | Conferences | Finance

DBV Technologies to Attend Upcoming Investor Conferences

News • 05/20/2015 | Corporate

Publication of the Resolutions Proposed to the Mixed General Assembly of DBV

News • 05/05/2015 | Conferences | Corporate | Finance

DBV Technologies to Present at Upcoming Investor Conferences

News • 04/30/2015 | Corporate | Finance

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

News • 04/29/2015 | Corporate | Finance

Topline Financial Results for First Three Months of 2015

News • 04/28/2015 | Corporate | Finance

DBV Technologies Selected to Enter Euronext’s Tech 40 Label

News • 04/15/2015 | Conferences | Corporate | Science

DBV Technologies to Present Viaskin® Data at the 2015 EAACI Congress

News • 04/09/2015 | Corporate | Product Candidates

DBV Technologies Receives FDA Breakthrough Therapy Designation for Viaskin Peanut for the Treatment of Peanut Allergy in Children

News • 03/25/2015 | Corporate | Finance

DBV Technologies Reports Full Year 2014 Financial Results

News • 03/10/2015 | Corporate

DBV Technologies Appoints Daniel Soland to Board of Directors

News • 03/06/2015 | Conferences | Finance

DBV Technologies to Present at Upcoming Investor Conferences

News • 02/24/2015 | Conferences | Science

Viaskin® Data Presented at AAAAI Meeting Show Safety and Efficacy in the Treatment of Food Allergies

News • 02/13/2015 | Corporate | Science

DBV Technologies Welcomes Dr. J-P Moreau to its Scientific Advisory Board

News • 02/03/2015 | Conferences | Finance

DBV Technologies to Present at the 2015 Leerink Partners Global Healthcare Conference in New-York (USA)

News • 02/03/2015 | Conferences | Science

Largest Presence Ever of DBV Technologies at 2015 Allergy Meeting

News • 01/29/2015 | Corporate | Finance

DBV Technologies Announces Topline Financial Results   for Full Year 2014  

News • 01/14/2015 | Corporate | Finance

Half year update on the DBV Technologies liquidity agreement

News • 01/12/2015 | Science

DBV Technologies Announces Publication in the Journal of Allergy and Clinical Immunology of Data Demonstrating that Epicutaneous Immunotherapy may Influence the Natural History of Allergy

News • 01/08/2015 | Corporate

DBV Technologies Provides Organizational Update

News • 11/20/2014 | Clinical | Product Candidates

DBV Technologies Initiates Phase I/II Clinical Trial with Viaskin Milk for the Treatment of Children with Cow’s Milk Allergy

News • 10/23/2014 | Corporate | Finance

Global offering of DBV Technologies ordinary shares

Over-allotment option exercised in full
Download PDF

News • 10/22/2014 | Corporate | Finance

DBV Technologies S.A. Announces Pricing of Global Offering

News • 10/20/2014 | Corporate | Finance

DBV Technologies S.A. Announces Proposed Global Offering

News • 10/14/2014 | Conferences | Finance

DBV Technologies Announces Topline Financial Results for First Nine Months 2014

News • 09/22/2014 | Clinical | Science

DBV Technologies Announces Primary Endpoint Met in VIPES, Viaskin Peanut’s Phase IIb Clinical Trial in Peanut Allergy

News • 07/17/2014 | Clinical | Partnership | Product Candidates

Consortium of Food Allergy Research Completes Recruitment of NIH-sponsored CoFar6 Phase II Trial with DBV’s Viaskin® Peanut in Treatment of Peanut Allergy

News • 06/16/2014 | Corporate | Finance

DBV Technologies to Present at Upcoming US Investors Conferences

News • 06/10/2014 | Conferences | Science

Five Scientific Communications at the European Academy of Allergy and Clinical Immunology Congress Further Support DBV’s EPITTM Disease Modifying Effect

News • 05/13/2014 | Clinical | Partnership | Product Candidates

DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children

News • 05/12/2014 | Corporate | Finance

DBV Technologies to Host and Webcast Investor Day in New York City on May 21, 2014

News • 04/17/2014 | Corporate | Finance

DBV Technologies publishes its 2013 Registration Document and its 2013 Annual Financial Report

News • 04/16/2014 | Clinical | Conferences | Product Candidates

DBV Announces the First reported case of a long term sustained effect of Peanut desensitization after Epicutaneous Immunotherapy (EPITTM) with Viaskin® at the French Congress of Allergy

CFA 2014 - Clinical Abstract
Download PDF

News • 04/16/2014 | Clinical | Conferences | Product Candidates

CFA 2014 – Clinical Abstract

DBV Announces the First reported case of a long term sustained effect of Peanut desensitization after Epicutaneous Immunotherapy (EPIT) with Viaskin® at the French Congress of Allergy
Download PDF

News • 04/15/2014 | Corporate | Finance

DBV Technologies Announces Topline Financial Results   for First Three Months 2014  

News • 04/09/2014 | Corporate | Partnership | Science

DBV Technologies and CEA conclude a scientific cooperation to investigate epigenetic modulation in epicutaneous immunotherapy

News • 04/07/2014 | Corporate

DBV Technologies Announces Creation of US Subsidiary and Appoints Ms. Susanna Mesa as Vice President of Finance, US Investor Relations & Strategy

News • 03/25/2014 | Conferences | Science

DBV Announces Data Presentations for EPIT at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2014

News • 03/17/2014 | Clinical | Corporate | Finance

DBV Technologies Reports Full Year 2013 Financial Results and Provides VIPES Update

News • 03/04/2014 | Conferences | Science

Presentation and Publication of Research at AAAAI Demonstrates EPITTM’s Ability to rebalance the Immune System and Induce a Disease-Modifying Effect

News • 02/18/2014 | Corporate | Partnership | Science

DBV Technologies and Mount Sinai Hospital Enter Research Collaboration for Crohn’s Disease

News • 01/30/2014 | Corporate | Finance

DBV Technologies Reports Full Year 2013 Topline Financial Results

News • 12/17/2013 | Clinical | Corporate | Product Candidates | Science

DBV provides 2013 year-end summary and news flow guidance for 2014

News • 12/13/2013 | Clinical | Conferences | Product Candidates | Science

Dr. Hugh Sampson presents Epicutaneous Immunotherapy for Food Allergy at the World Allergy Organization Conference

News • 11/26/2013 | Corporate | Partnership | Science

DBV Technologies Enters into Collaboration Agreement with BioNetAsia and University of Geneva on Whooping Cough Booster Vaccine

News • 11/14/2013 | Corporate | Finance

DBV Technologies announces the completion of a €29.9m private placement with a majority placed with US investors

News • 10/24/2013 | Clinical | Partnership | Product Candidates

NIH-sponsored Consortium of Food Allergy Research (CoFAR) starts a Phase II clinical study with DBV Technologies’ Viaskin® Peanut in the treatment of peanut allergy

News • 10/22/2013 | Corporate | Partnership | Science

DBV Technologies Forms Research Collaboration with Inserm to Develop Viaskin® for Refractory Hemophilia A Disease

News • 10/18/2013 | Clinical | Corporate | Partnership | Product Candidates | Science

Stallergenes and DBV Technologies Announce Respiratory Allergy Research and Development Collaboration for Birch Pollen

News • 10/15/2013 | Clinical | Corporate | Finance

DBV Announces Topline Financial Results for First Nine Months 2013 and Provides Safety Update on Viaskin® Peanut

News • 09/04/2013 | Clinical | Product Candidates

DBV Technologies initiates a long-term follow-up study of Viaskin Peanut

News • 07/08/2013 | Clinical | Product Candidates

DBV Technologies completes enrollment of Phase IIb VIPES study, the first-ever global trial in desensitization to peanut allergy

News • 06/28/2013 | Conferences | Science

DBV Technologies announces breakthrough Data Presentations at EAACI-WAO Congress

News • 06/20/2013 | Clinical | Partnership | Product Candidates

Viaskin Peanut demonstrates strong efficacy trend in severely peanut-allergic children in 18-month results of ARACHILD pilot study

News • 05/16/2013 | Clinical | Partnership | Product Candidates | Science

Stallergenes and DBV Technologies enter into partnership for the development of innovative treatment of respiratory allergies

News • 05/07/2013 | Corporate | Partnership | Science

DBV Technologies and Mount Sinai Hospital enter into a Research Collaboration Agreement

News • 04/25/2013 | Corporate | Finance

DBV Technologies publishes its 2012 Registration Document and its 2012 Annual Financial Report

News • 03/05/2013 | Corporate | Finance | Partnership

DBV Technologies enters into a strategic manufacturing agreement with Sanofi

News • 03/04/2013 | Corporate | Finance | Science

DBV Technologies reports Full Year 2012 financial results and provides R&D update

News • 01/31/2013 | Clinical | Corporate | Finance | Science

DBV Technologies Reports Full Year 2012 Topline and Provides an Update on R&D Activities

News • 01/15/2013 | Corporate | Partnership | Science

DBV Technologies and INRA receive funding to develop pediatric bronchiolitis (‘RSV’) vaccine: RSV-NanoViaSkin

News • 12/18/2012

DBV Technologies’ 2013 Financial calendar

News • 11/14/2012 | Clinical | Corporate | Product Candidates | Science

DBV Technologies launches its third Viaskin® program, a first for the treatment of House Dust Mites (HDM) allergy in young children

News • 10/16/2012 | Corporate | Science

DBV Technologies and Centre d’Immunologie de Marseille-Luminy (CIML) enter in a Collaboration Agreement

News • 10/15/2012 | Corporate | Finance

First nine months topline and clinical and business highlights

News • 08/02/2012 | Clinical | Corporate | Product Candidates

DBV Technologies initiates VIPES phase IIb clinical study, the first global trial ever in desensitization of peanut-allergic children and adults

News • 07/26/2012 | Clinical | Corporate | Science

Half Year 2012 results and R&D highlights: DBV Technologies on track

News • 07/19/2012 | Corporate | Science

DBV Technologies welcomes Mr. Stef Koppelman as its new General Scientific Advisor

News • 06/18/2012 | Clinical | Conferences | Product Candidates

DBV Technologies presents detailed results of a clinical study showing that VIASKIN® is safe and well-tolerated by peanut-allergic patients at the EAACI congress

News • 06/18/2012 | Clinical | Product Candidates

Positive interim clinical data in peanut allergic children treated with VIASKIN PEANUT

News • 05/31/2012 | Corporate | Science

Professor Hugh Sampson joins Scientific Advisory Board of DBV Technologies

News • 05/15/2012 | Clinical | Finance | Science

First quarter 2012 topline, scientific activity and upcoming clinical data

News • 05/10/2012 | Corporate

DBV Technologies welcomes Charles Ruban as Chief Development Officer

News • 03/28/2012 | Corporate | Finance

Successful Initial Public Offering (IPO) for DBV Technologies

News • 02/28/2012 | Clinical | Product Candidates | Science

Viaskin Peanut receives FDA “Fast Track Designation”

News • 01/31/2012 | Corporate | Finance

DBV Technologies announces the filing of its “Document de Base” with the French Autorité des marchés financiers

News • 12/06/2011 | Corporate | Finance

DBV Technologies introduces its new Chief Financial Officer

News • 09/21/2011 | Corporate

DBV Technologies moves to Bagneux

News • 06/08/2011 | Clinical | Science

DBV Technologies VIASKIN® technology has been chosen to feature on the cover of the European Journal of Allergy and Clinical Immunology June 2011 issue in its timeline “100 years allergen specific immunotherapy.”

News • 01/18/2011 | Corporate | Science

DBV Technologies elects George Horner as non­ executive Chairman

News • 01/08/2011 | Corporate | Science

DBV Technologies is very proud to have been chosen to feature on the cover of the Journal of Allergy and Clinical Immunology January 2011 issue

News • 01/05/2011 | Corporate | Finance

DBV Technologies closes $25.5 (€19,4) million Series ‘C’ financing round

News • 09/23/2010 | Corporate | Finance | Product Candidates

DBV Technologies Granted US Patents for Allergen Delivery System VIASKIN®

News • 09/01/2010 | Clinical | Product Candidates

VIASKIN® PEANUT Selected for U.S. Consortium of Food Allergy Research’s Peanut Allergy Desensitization Trial

News • 07/06/2010 | Clinical | Product Candidates

DBV Technologies Receives IND Clearance From FDA to Begin Clinical Trial in Peanut Allergy

News • 06/14/2010 | Corporate | Science

DBV Technologies expands Scientific Advisory Board with appointment of leading US allergy specialists

News • 12/18/2009 | Corporate

DBV Technologies appoints Professor Robert Zeiger to its Scientific Advisory Board

News • 10/19/2009 | Corporate

DBV Technologies appoints Professors Gideon Lack and Philippe Eigenmann to its Scientific Advisory Board

News • 04/15/2009 | Corporate | Partnership

DBV Technologies signs strategic agreement with Assistance Publique-Hôpitaux de Paris (AP-HP) office of technology transfer and industrial partnerships

News • 02/19/2009 | Corporate

DBV Technologies expands its Board of Directors

News • 01/22/2009 | Corporate | Finance

DBV Technologies raises €6 million in Series B investment and secures new corporate investor

News • 11/13/2007 | Corporate | Science

DBV Technologies Strengthens Board of Directors and Scientific Advisory Board

News • 01/23/2006 | Corporate | Finance

Sofinnova and Apax Partners invest €12 million in DBV Technologies